A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
Latest Information Update: 06 Sep 2024
At a glance
- Drugs BMS 986012 (Primary) ; Carboplatin; Cisplatin; Etoposide; Platinum complexes
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 Sep 2024 Status changed from active, no longer recruiting to completed.
- 21 May 2024 Planned End Date changed from 29 Jun 2024 to 3 Jun 2024.
- 12 Jan 2024 Planned End Date changed from 29 Dec 2023 to 29 Jun 2024.